JUNSHI BIO (01877): Tuoyi New Indication Included in the National Medical Insurance Catalog
JUNSHI BIO (01877) announced that recently, the indication of the Company's product toripalimab injection (trade name: Tuoyi, product code: JS001) in combination with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma was successfully included in the Class B scope of the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" (hereinafter referred to as the "National Medical Insurance Catalog"). The new version of the National Medical Insurance Catalog will be officially implemented starting January 1, 2027.
JUNSHI BIO (01877) announced that recently, the indication of its product toripalimab injection (trade name: Tuoyi, product code: JS001) in combination with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma was successfully included in the Class B scope of the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2026)" (hereinafter referred to as the "National Medical Insurance Catalog"). The new version of the National Medical Insurance Catalog will be officially implemented starting January 1, 2027.
As of the disclosure date of this announcement, all 13 indications of Tuoyi approved for marketing in mainland China have been included in the National Medical Insurance Catalog, making it the only anti-PD-1 monoclonal antibody drug in the catalog for the treatment of triple-negative breast cancer, melanoma, first-line renal cancer, and first-line urothelial carcinoma.
Toripalimab injection is China's first domestically approved monoclonal antibody drug targeting PD-1 and has won the "China Patent Gold Award," the highest award in the national patent field. In December 2020, toripalimab injection passed the national medical insurance negotiation for the first time. As of the disclosure date of this announcement, all 13 indications approved in mainland China have been included in the National Medical Insurance Catalog, making it the only anti-PD-1 monoclonal antibody drug in the National Medical Insurance Catalog for the treatment of triple-negative breast cancer, melanoma, first-line renal cancer, and first-line urothelial carcinoma.
In terms of international layout, as of the disclosure date of this announcement, toripalimab has achieved a presence across six continents globally, having been approved for marketing in more than 50 countries and regions including China, the United States, and Europe, with marketing applications submitted/accepted in multiple countries and regions.
The inclusion of Tuoyi's new indication in the National Medical Insurance Catalog this time reflects the National Healthcare Security Administration's (hereinafter referred to as the "National Healthcare Security Administration") recognition of Tuoyi's clinical value, patient benefits, and degree of innovation, and highlights the state's emphasis on and support for drug research and development and industrialization by domestic innovative pharmaceutical companies.
The results of this medical insurance negotiation will help the company further improve the affordability and accessibility of Tuoyi for patients, help further promote the market promotion of commercialized products and increase sales scale, and have a positive impact on the company's long-term business development. The company will actively cooperate in advancing the implementation of medical insurance policies, continue to advance hospital access work, and expand coverage in core markets and broad markets, with the aim of continuously improving patient access to medication.
Related Articles

ENVISION GREEN (01783) signs another locked-card agreement, strengthening its compliant rental calculation logic.

GMTEight List of A-share restricted sales and lifting restrictions | November 16

A-share Pre-market Briefing | Wu Qing Makes Major Remarks Over the Weekend! NVIDIA Corporation (NVDA.US) Set to Report Earnings Soon
ENVISION GREEN (01783) signs another locked-card agreement, strengthening its compliant rental calculation logic.

GMTEight List of A-share restricted sales and lifting restrictions | November 16

A-share Pre-market Briefing | Wu Qing Makes Major Remarks Over the Weekend! NVIDIA Corporation (NVDA.US) Set to Report Earnings Soon






